SOC ( DrugBank: - )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
47	バージャー病	1
158	結節性硬化症	2

47. バージャー病

臨床試験数 : 9 / 薬物数 : 13 - (DrugBank : 7) / 標的遺伝子数 : 6 - 標的パスウェイ数 : 15

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02501018 (ClinicalTrials.gov)	November 1, 2017	14/7/2015	Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI)	A Prospective, Open Label, Controlled, Randomized, Multicenter Study to Assess the Efficacy and Safe ...	Critical Limb Ischemia;Buerger Disease;Thromboangiitis Obliterans;Atherosclerosis Obliterans	Biological: CLBS12;Drug: SOC	Caladrius Biosciences, Inc.	NULL	Recruiting	20 Years	85 Years	All	35	Phase 2	Japan

臨床試験数 : 108 / 薬物数 : 67 - (DrugBank : 17) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 118

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04485104 (ClinicalTrials.gov)	May 19, 2021	21/7/2020	Safety, Pharmacokinetics, and Exploratory Efficacy Assessment of Adjunctive Cannabidiol Oral Solutio ...	An Open-label, Randomized Trial to Assess the Safety, Pharmacokinetics, and Exploratory Efficacy of ...	Seizure in Participants With Tuberous Sclerosis Complex	Drug: GWP42003-P;Drug: SOC	GW Research Ltd	NULL	Recruiting	1 Month	11 Months	All	12	Phase 3	United States
2	NCT01031901 (ClinicalTrials.gov)	December 2009	10/12/2009	Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) ...	Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex and Ne ...	Tuberous Sclerosis;Neurofibromatoses;Angiofibroma;Neurofibroma	Drug: Skincerity;Drug: Skincerity plus sirolimus/rapamycin;Drug: Skinercity plus sirolimus/rapamycin ...	The University of Texas Health Science Center, Houston	Society for Pediatric Dermatology	Completed	13 Years	N/A	Both	52	Phase 1	United States